Organicell Regenerative Medicine, Inc.
OCEL · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.20 | 0.01 | -0.05 |
| FCF Yield | -2.47% | -1.27% | 0.58% | -4.69% |
| EV / EBITDA | -5.38 | -7.74 | -8.40 | -12.76 |
| Quality | ||||
| ROIC | 94.35% | 69.77% | 69.84% | -3,538.85% |
| Gross Margin | 82.54% | 77.72% | 82.48% | 61.07% |
| Cash Conversion Ratio | 0.12 | 0.10 | -0.05 | 108.22 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.67% | -9.21% | 462.83% | 456.60% |
| Free Cash Flow Growth | -95.80% | -320.00% | 112.35% | 36.68% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.32 | 0.57 | 0.78 |
| Interest Coverage | -90.04 | -66.38 | -56.95 | 1.57 |
| Efficiency | ||||
| Inventory Turnover | 0.88 | 1.09 | 0.78 | 1.90 |
| Cash Conversion Cycle | 101.91 | 83.56 | 116.02 | 63.04 |